Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on August 9, 2013. The report announces the Company's financial results and provides a business and clinical update for the three and six months ended June 30, 2013. The detailed results are contained in a press release attached as Exhibit 99.01.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.01) but are not disclosed within the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It directs readers to the attached press release for the announcement of financial results and clinical updates.
Guidance, Outlook, and Risks
The Company provided a business and clinical update alongside the financial results. The filing includes a standard disclaimer stating that the information furnished under Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of such section.
Investor Verification Checklist
- Review Exhibit 99.01 (Press Release Dated August 9, 2013) for specific revenue, net loss, and cash position figures.
- Verify the details of the clinical update mentioned in the press release.
- Confirm the Company's cash runway and funding status as detailed in the full press release.
- Note that the financial data in the press release is not considered "filed" under Section 18 of the Exchange Act.